AWS Health Innovation Podcast

Imagine if a baby's cries were no longer a mystery, but a window into their needs and well-being. Today we welcome Zoundream to the show, a company focused on transforming infant care through advanced cry analysis. Roberto Iannone, CEO and Founder of Zoundream, joins Alex Merwin, Head of Growth for Healthcare & Life Sciences Startups at AWS, to discuss Zoundream's groundbreaking solution that utilizes AI to analyze infant cries and sounds in real-time, pinpointing reasons such as hunger or tiredness with remarkable accuracy and also detecting digital biomarkers for conditions like autism, with the potential for providing lifelong benefits for babies and their families by enabling earlier diagnosis. How does Zoundream's AI solution decode baby needs? Zoundream's pioneering AI solution analyzes infant cries to accurately identify needs like hunger or tiredness. This technology has the potential to improve infant care by providing real-time insights into babies' states before they can communicate verbally. What progress has Zoundream made in autism early detection? Remarkably, Zoundream's cry analysis can detect early signs of autism spectrum disorder, enabling timely interventions. This groundbreaking application highlights the potential of vocal biomarkers in diagnosing developmental conditions. How did Zoundream involve healthcare professionals in developing their solution? From the outset, Zoundream involved pediatricians and neuropsychologists to ensure their solution addressed valuable clinical applications. This collaborative approach was crucial in building credibility and onboarding hospital partners for data gathering. What motivated Roberto Iannone's transition from corporate to entrepreneurship? Roberto Iannone transitioned from a corporate career to entrepreneurship, driven by the autonomy of being a founder/CEO. This pivotal decision enabled him to pursue his vision of transforming infant care globally. What is Zoundream's approach to regulatory compliance for clinical adoption? Recognizing the regulatory requirements for clinical applications, Zoundream meticulously tests and versions their AI models. Learn more about Zoundream here to understand how their innovative solution is transforming infant care. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.

To scale health innovation, we need to take a broad view and redefine the art of the possible in Real-World Evidence, Data & Population Health. In the fifth and final episode of our Health Innovation Compilation Series, we hear from Mendel, Akrivia Health, Epistemix, Ovation, and Evidation Health, innovative companies that are transforming how we leverage data to drive better health outcomes. 1. How does Mendel reconcile conflicting medical data? Mendel's AI structures unstructured patient data into coherent journeys, reconciling conflicting information from sources like pathology reports and genomics. It enables querying consolidated data through intuitive interfaces, providing faster answers backed by evidence. 2. How is Akrivia Health unlocking insights in mental health? Akrivia Health uses AI/NLP to curate and deidentify unstructured clinical notes from electronic medical records, translating them into structured data for mental health research. This enables safe data sharing and treatment development for mental health and dementia. 3. How does Epistemix simulate population health interventions? Epistemix created a synthetic US population to model infectious disease spread, expanding to chronic conditions and social determinants. Their simulations evaluate cascading effects of interventions like faster testing on community outcomes. 4. How is Ovation bridging genomics and healthcare? Ovation envisioned being a genomic data company, building a biobank and research network from diagnostic lab data. Linking genomic and longitudinal patient data enables studying disease origins and advancing therapeutics. 5. How does Evidation Health incentivize healthy user behaviors? Evidation Health incentivizes users to contribute real-world data from wearables to impactful research studies. This provides insights into health outside clinical settings for disease prevention and management. Featured Companies: Mendel: Karim Galil, Co-founder & CEO (https://www.mendel.ai/about, Full Episode) Akrivia Health: David Newton, COO & Co-Founder (https://akriviahealth.com/, Full Episode) Epistemix: John Cordier, CEO & Co-Founder (https://www.epistemix.com/, Full Episode) Ovation: Barry Wark, Co-Founder & Chief Strategy Officer, Curt Medeiros, Chief Executive Officer (https://www.ovation.io/, Full Episode) Evidation Health: Alessio Signorini, CTO (https://evidation.com/, Full Episode) Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Think back to the last time you received healthcare, whether it was an emergency or routine checkup - how was your experience? In Part Four of our Health Innovation Compilation Series, we learn about a set of remarkable companies working to uplift the clinician and patient experience. From Aneesh Chopra, President of CareJourney, to Elad Walach, CEO of Aidoc, Adrian Aoun, CEO & Founder of Forward, Paul Roscoe, CEO of CLEW, and Robin Shah, Co-Founder & CEO of Thyme Care, this episode showcases the cutting-edge technologies transforming how we give and receive care. How are companies leveraging predictive analytics to empower clinicians? CareJourney utilizes claims data to predict disease progression, providing signals back to providers with actionable steps to close care gaps for over 300M people. Aidoc's AI platform analyzes medical data across specialties, enabling proactive clinical interventions and aiding care teams in optimizing patient treatment. How is Forward reimagining healthcare delivery through technology? Forward envisions healthcare as a scalable product, leveraging technology to enable preventive, data-driven, and self-controlled care, challenging traditional healthcare models. How is AI being used to improve clinical quality and identify risks? Clew Medical's AI platform identifies high-risk patients before deterioration, using physiological data and predictive models to alert clinicians, expanding beyond ICUs and FDA-cleared for some models. How are companies addressing the challenges of navigating cancer care journeys? Thyme Care partners with health plans, pairing oncology nurses and software to facilitate whole-person cancer care, addressing disparities and aligning treatment with patient goals. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. Featured Companies: CareJourney - Full Episode Guest: Aneesh Chopra, President Website: https://www.carejourney.com/ Aidoc - Full Episode Guest: Elad Walach, CEO Website: https://aidoc.com/ Forward Health - Full Episode Guest: Adrian Aoun, CEO & Founder Website: https://goforward.com/ CLEW - Full Episode Guest: Paul Roscoe, CEO Website: https://clewmed.com/ Thyme Care - Full Episode Guest: Robin Shah, Co-Founder & CEO Website: www.thymecare.com

Reimagining clinical trials through innovation and technology. In this compilation episode, part 3 of our Health Innovation Series, we explore how Deep6 AI, CEO Wout Brusselaers, Lokavant, CEO Rohit Nambisan, and Science 37, Chief Delivery Officer Darcy Forman, are transforming the way clinical trials are conducted. How is Deep6 AI revolutionizing patient recruitment for clinical trials? Deep6 AI leverages AI and natural language processing to precisely match eligible patients to clinical trials by mining real-world data from electronic medical records (EMRs). This enables faster recruitment, fewer dedicated resources, and de-risking of research efforts for hospitals, life sciences companies, and contract research organizations (CROs). Traditional recruitment methods relied on physicians identifying eligible patients or querying structured data, leading to large pools requiring manual review. Deep6AI ingests all patient data into a cloud platform and uses NLP to create multi-dimensional patient vectors, enabling precise matching by searching a small pool of truly eligible patients. How is Lokavant transforming clinical trial operations? Lokavant was founded to solve operational challenges in clinical trials that existing systems could not handle. Their platform ingests diverse data sources and enables configurable analytics across use cases like site/safety monitoring and enrollment forecasting, leveraging data from over 2,000 studies for predictive analytics. How is Science 37 decentralizing clinical trials globally? Science 37 brings clinical trial access to diverse patient populations through a virtual/decentralized model, leveraging technology to orchestrate remote visits and engagement. Their network of investigators and mobile nurses enables enrollment of underserved communities matching census data demographics. Science 37's "meta-site" virtual site enables remote participation through a single app, overcoming roadblocks to drive an innovative, patient-centric clinical trial delivery model. Patients develop strong rapport with nurses, expressing gratitude for in-home care during trials. Featured Companies: Deep6 AI - Wout Brusselaers, CEO & Founder Website: https://deep6.ai/ Full Episode: Link to episode Lokavant - Rohit Nambisan, CEO Website: https://www.lokavant.com Full Episode: Link to episode Science 37 - Darcy Forman, Chief Delivery Officer Website: www.science37.com Full Episode: Link to episode Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.

In part two of our five part compilation mini-series on health innovation we explore groundbreaking advancements in diagnostics and biomarkers. 1. How is Us2.AI democratizing cardiac care through AI-powered echocardiograms? Us2.AI is revolutionizing cardiac imaging by automating echocardiogram analysis with AI, enabling non-specialists to perform accurate heart scans. This empowers early diagnosis and treatment in underserved areas. Co-founders James Hare and Dr. Carolyn Lam share insights on their AI-Echo software, which is utilized globally in clinical practice settings to improve patient outcomes and expand healthcare access. 2. What is Truvian's innovative approach to disrupting blood diagnostics? Truvian is developing a benchtop system that can provide lab-accurate blood test results in 20 minutes from a small sample, aiming to increase access to routine health screenings. CEO Jay Srinivasan discusses their proprietary approach, which they are seeking FDA clearance and CLIA waiver for, to deliver accessible blood testing from one small blood sample in minutes. 3. How is Sparta Science optimizing human movement and performance? Sparta Science's force plate technology captures detailed movement data to identify injury risks and guide interventions, improving human performance across various conditions and clinical trials. Founder & CEO Dr. Phil Wagner shares insights on their journey from democratizing force plate technology to evolving into a human data platform reshaping the landscape of human measurement. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. Featured Companies: Us2.AI - James Hare (Co-founder/CEO), Dr. Carolyn Lam (Co-Founder & Non-Exec Head of Medical Affairs) - Company Website, Full Episode Truvian Health - Jay Srinivasan (CEO) - Company Website, Full Episode Sparta Science - Phil Wagner (Founder & CEO) - Company Website, Full Episode

Join Andrei Georgescu (VivoDyne CEO), Serafim Batzoglou (Seer Chief Data Officer), Dave Longo (Ordaōs CEO), Alex Zhavoronkov (Insilico Medicine Founder), and Young Kwon (Alchemab Therapeutics PhD) as they revolutionize drug R&D. Discover how VivoDyne's bioengineering platform is transforming tissue sample research. Learn about Seer's nanoparticle technologies that unveil more proteins than ever. Uncover Ordaōs' innovative mini-proteins reshaping drug development and the impact of AI on discovering therapies for complex diseases. It's a deep dive into the future of medicine!

In this episode of the AWS Health Innovation Podcast, Yin He, Principal Business Development for Healthcare and Life Sciences Startups, interviews Karim Galil, Co-Founder and CEO of Mendel. Mendel harnesses the power of AI to structure unstructured patient data, building comprehensive patient journeys that reconcile conflicting data points and empower healthcare professionals with a more objective, data-driven approach to medicine. How does Mendel unlock the potential of medical data? Mendel.ai aims to structure unstructured clinical data and reconcile conflicting information to generate comprehensive patient journeys. This approach moves medicine towards more objective, data-driven practices while accounting for physician expertise. How does Mendel bridge the divide between technical and non-technical users? Mendel caters to both technical (data analysts) and non-technical (clinicians) users by providing explainable AI systems that foster trust and adoption. Responsible marketing highlighting capabilities and limitations is crucial. What is Mendel's approach to AI in healthcare? Mendel combines deep learning with a knowledge graph representation, ensuring explainability and consistency in medical AI outputs. This paves the way for an "Iron Man and Jarvis" collaborative relationship between physicians and advanced AI systems. What entrepreneurial traits does Karim Galil emphasize? Karim Galil draws inspiration from personal experiences as a physician, emphasizing resilience, passion for problem-solving, and a mindset of continuous improvement as key traits for aspiring entrepreneurs in the healthcare AI space. What is Mendel's vision for indexing medical knowledge? Mendel envisions a future where a company can index and make sense of all medical records, akin to libraries for books and Google for the internet, revolutionizing healthcare delivery through comprehensive data accessibility. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. To learn more about Mendel, visit their website at mendel.ai.

Pushing the boundaries of human biology, Vivodyne has developed a groundbreaking microfluidic bioengineering platform capable of growing tens of thousands of human tissue samples at scale. Our guest is Andrei Georgescu, the CEO of Vivodyne, whose unique background bridging electrical engineering and bioengineering led him to develop this innovative approach. Hosting the interview is Yin He, Principal Business Development for Healthcare and Life Sciences Startups at AWS, who will explore how Vivodyne's platform combines the principles of organs-on-chips and organoids at high throughput. How does Vivodyne's microfluidic platform revolutionize drug discovery? Vivodyne's microfluidic bioengineering platform enables growing tens of thousands of human tissue samples at scale, providing unprecedented insights into human biology before clinical trials. This approach aims to revolutionize drug discovery success rates by gathering massive human data currently lacking. What is the key innovation behind Vivodyne's approach? Rather than top-down engineering, Vivodyne leverages principles of organs-on-chips and organoids to enable bottom-up self-assembly of complex human tissues at high throughput. This allows studying tissue interactions, systemic effects like immune responses, and linking multiple systems to model integrated physiology. How does Vivodyne's platform align with ethical principles? By producing foundational human data on gene edits, drug metabolism, off-target effects and more, Vivodyne's automated microfluidic platform displaces animal testing facilities while significantly reducing costs. This aligns scientific advancement with ethical principles. What challenge is Vivodyne tackling, and how? Integrating isolated biological knowledge into a holistic, system-level understanding remains extremely challenging. Vivodyne is tackling this immense complexity by combining microfluidics' control with high-throughput human tissue data generation to enable AI modeling of human biology at unprecedented scales. What advice does Vivodyne's CEO have for biotech entrepreneurs? As a biotech entrepreneur, Vivodyne's CEO Andrei Georgescu advises tackling very difficult yet high-impact problems, as the potential upside outweighs incremental approaches despite perceived higher risk. Transformative innovation requires embracing immense challenges. To learn more about Vivodyne's groundbreaking work, visit their website at vivodyne.com. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Imagine being able to design novel drug molecules with the same ease as typing words into a computer, and being given the instructions into how to synthesize that molecule in the lab. That's the incredible potential of Iktos, our guest on today's episode of the AWS Health Innovation Podcast hosted by Alex Merwin, Head of Growth for Healthcare & Life Sciences Startups at AWS, and featuring Yann Gaston-Mathé, the Founder & CEO of Iktos. 1. How is Iktos revolutionizing the field of drug discovery with AI? Iktos' groundbreaking approach harnesses deep generative AI models trained on vast molecular databases to automatically design novel, optimized molecules for drug discovery challenges. This innovative technology promises to accelerate pharmaceutical R&D by rapidly generating promising molecular candidates tailored to specific therapeutic targets. 2. What is the unconventional journey of Iktos' founder, Yann Gaston-Mathé? Yann Gaston-Mathé, Iktos' founder and CEO, followed an atypical path, publishing his first academic paper at over 40 after diverse experiences spanning engineering, biology, consulting, and entrepreneurship before embracing the AI innovation that became Iktos. 3. What is Iktos' integrated AI-robotics platform, and how does it provide a competitive advantage? Iktos developed an integrated AI-robotics platform to automate molecular synthesis and generate real-world data for active learning, recursively improving its AI models' performance through continuous feedback loops, a key competitive advantage. 4. How has Iktos demonstrated the transformative impact of its technology in drug discovery? Leveraging its AI expertise, Iktos successfully optimized drug candidates for a Japanese pharma client, meeting 7-8 out of 8 success criteria within 12 months, demonstrating the transformative potential of its technology in accelerating drug discovery pipelines. 5. How does Iktos foster a culture of multidisciplinary innovation? Iktos cultivates a collaborative culture promoting cross-team knowledge sharing and brainstorming between AI, computational chemistry, and medicinal chemistry experts, fostering multidisciplinary innovation at the convergence of these fields. Learn more about Iktos and their AI-driven drug discovery solutions on their website. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Exploring the intersection of AI and biology, this episode features Jonathan Baptista, Co-Founder and CEO of DeepLife. DeepLife uses machine learning to curate and annotate single-cell RNA-seq datasets, enabling downstream bioinformatics analysis and target identification. Host Alex Merwin from AWS learns all about DeepLife's groundbreaking approach to accelerating drug discovery and precision medicine through AI-driven simulations and generative models. How does DeepLife leverage AI for drug discovery simulations? DeepLife creates digital twins of cells, enabling virtual experimentation and mechanistic modeling to identify potential drug targets without extensive lab testing. Their platform simulates cellular responses to perturbations, providing insights into disease mechanisms and therapeutic opportunities. What inspired Jonathan Baptista's pivot from aerospace to computational biology? Jonathan's background in aerospace engineering inspired applying simulation tools to complex biological systems, inferring "laws" from data using AI/ML techniques instead of defined physics equations. This approach aims to accelerate drug discovery for precision medicine. How does DeepLife map the biomolecular landscape? DeepLife spent years developing pipelines to harmonize and annotate high-quality biomolecular data from public repositories and partners, mapping available datasets to identify therapeutic areas suitable for their AI-driven modeling approach. How does DeepLife leverage generative AI for biomedicine? Leveraging recent advances in generative AI models for text and images, DeepLife improved annotation and simulation of cell states after perturbations, benchmarking and selecting optimal techniques for different drug discovery tasks. What is DeepLife's "collaborative AI" approach? DeepLife's "collaborative AI" approach generates potential biological hypotheses that researchers can validate and explore further, enabling visualization of simulated cells and predicted perturbations to uncover novel mechanistic insights. Learn more about DeepLife here and their mission to build the next generation of system biology. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.